Gregory Harris is a strategic executive with two decades of experience managing people, projects, and products in the medical device industry. He brings a proven track record in startup operations, crisis leadership, and supply chain management. As a seasoned engineer, he is expert in overseeing vertically integrated production lines and directing teams to craft problem-solving solutions. What sets him apart is his Silicon Valley experience fostering innovation and efficient operations as director for the cross-cutting divisions of a major scientific company. He has held positions of progressively increasing responsibility in locations around the world—all while consistently advancing the company’s mission and optimizing global operations.DIRECTING OPERATIONS AND ENGINEERING• Demonstrated strategic vision by creating and designing product business plans, project parameters, and strategies for potential business opportunities. Outlined key resource requirements and timelines, including pricing and positioning.• Spearheaded the team tasked with acquisition of Cameron Health. Led team through Six Sigma process to identify a breakdown in the glass molecular structure of Cameron’s Implantable Pulse Generator device, solving a problem in assembly that could cause electrical shorts and patient injury or death.DRIVING PROFIT AND PERFORMANCE• Developed operating budget, capacity plan, and forecasts for capital and labor allocation for $22M factory spend in capacitor and battery manufacturing.• Reduced overall builder time by 50% with a cost savings of $2.5M annually.• Successfully launched a Supply Chain Stability Program that reduced near-miss component stockouts and line uptime performance by 80% monthly.• Designed a daily quality review process that enabled the factory to identify early on any finished assemblies that did not conform, thereby reducing annual losses due to scrapping by $5M.MANAGING TRANSITION AND RISK• Optimized a multi-site plant network as Project Leader. Closed operations in Minnesota while securing approval to purchase, resource, and develop related operations in Clonmel, Ireland, resulting in $30M in tax-advantaged manufacturing.• Guided planning and operations for site decommission in 2021. PROMOTING LEGAL COMPLIANCE• Enabled Boston Scientific to resume product shipment and public trading on the stock market by guiding the company through Regulatory Submission Review.• Promoted compliance with federal FDA requirements.